New Antibiotic Effective in Treating Gram-Positive Bacteremia

Publication
Article
OncologyONCOLOGY Vol 14 No 3
Volume 14
Issue 3

Results from the compassionate use program for linezolid (Zyvox), an investigational new antibiotic still under development, show that the drug is effective in the treatment of patients with bacteremia associated with significant gram-positive infections,

Results from the compassionate use program for linezolid (Zyvox), an investigational new antibiotic still under development, show that the drug is effective in the treatment of patients with bacteremia associated with significant gram-positive infections, including those resistant to current therapies. These data were discussed at a poster session at the 37th annual meeting of the Infectious Diseases Society of America in Philadelphia.

Data were presented on 254 patients with bacteremia from 165 investigational sites. Of the total bacteremic population enrolled in the compassionate use program, 120 were clinically evaluable at short-term follow-up. Of this group, 82.5% were considered to be cured. A total of 64 patients were considered to be microbiologically evaluable at short-term follow-up, and linezolid demonstrated an 85.9% microbiologic cure rate in these individuals.

A third group of 50 patients was studied to assess how rapidly linezolid eradicated the bacteria from patients’ bloodstream. Linezolid eradicated organisms from the bloodstream by day 2 of treatment in approximately 50% of these patients and by day 5 in 75%.

 “Our data from the Zyvox compassionate use program suggest that Zyvox is well tolerated and successful in treating patients with bacteremia,” said study coordinator Mary Birmingham PharmD, program director, The Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, and State University of New York, Buffalo. “Zyvox is an excellent treatment option for these seriously ill patients with gram-positive bacteremia.”

Range of Infections Treated

The infections in the patients studied included documented intravenous or catheter-line infections, gastrointestinal infections, skin and soft-tissue infections, urinary tract infections, infected thrombi, and infected devices. The primary causative organism isolated from from the group was vancomycin-resistant Enterococcus faecium (81.4%). Other organisms isolated included methicillin-resistant Staphylococcus aureus (6.2%), methicillin-resistant S epidermidis (2.7%), other strains of vanco-mycin-resistant entercocci (2.7%), vancomycin-susceptible enterococci (2.7%), vancomycin-resistant E faecalis (2.3%), and methicillin-susceptible S aureus (1.2%).

Nonevaluability in a large number of patients was due to repeat baseline blood cultures being negative prior to the initiation of treatment with linezolid or to patients dying from their underlying illnesses. The overall adverse event rate was 25.2%, with 5.5% of these events considered to be serious and 9.0% requiring discontinuation of treatment.

Articles in this issue

Comparative Economic Analysis of the Treatment of Relapsed Low-Grade B-Cell Non-Hodgkin’s Lymphoma (NHL) in France Using CHOP, Fludarabine, or Rituximab
FHIT Gene, Smoking, and Cervical Cancer
Final Report on the Safety and Efficacy of Retreatment With Rituximab for Patients With Non-Hodgkins Lymphoma
Prospective, Randomized, Controlled Study of Zevalin Radioimmunotherapy Compared to Rituximab Immunotherapy for B-Cell, Non-Hodgkins Lymphoma: Interim Results
IOM Medical Error Estimates Questioned, But Legislation Considered
Less Toxic Therapies for Hodgkin’s Disease May Reduce Secondary Cancers
Preserving Fertility in Young Women With Ovarian Cancer Does Not Decrease Survival
Iodine-131 Tositumomab for Patients With Transformed, Low-Grade Non-Hodgkin’s Lymphoma: Overall Clinical Trial Experience
Survival Rates Significantly Worse For African-Americans With Endometrial Cancer
Rituximab Has Significant Activity in Patients With Chronic Lymphocytic Leukemia
Responders to Rituximab Show Continued Tumor Regression Over Time and a Progression-Free Survival That Correlates With Response Classification
PhRMA Criticizes FDA’s Proposed Rule on Antibiotic Approvals
Phase II Study of Rituximab in Combination With CHOP in Patients With Previously Untreated Intermediate- or High-Grade Non-Hodgkin’s Lymphoma
New Antibiotic Effective in Treating Gram-Positive Bacteremia
Reduced-Dose Zevalin Radioimmunotherapy for Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma Patients With Preexisting Thrombocytopenia: Report of Interim Results of a Phase II Trial
Recent Videos
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Although a similar proportion achieved MRD negativity at the 10 to the –6 power, not enough studies have analyzed MRD at this level for multiple myeloma.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
Related Content